



Section #11
J 1.10.02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Albert P. Tseng, et al.

Examiner: Yaen, Christopher H.

Serial No.: 09/831,744

Art Unit: 1642

Filed: January 25, 2001

Docket: 13030

For: PHOSPHOLIPASE INHIBITORS
FOR THE TREATMENT OF CANCER

Dated: January 3, 2003

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED
JAN 07 2003
TECH CENTER 1600/2900

RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143

Sir:

In response to the Office Action dated July 3, 2002, setting forth a requirement for species election, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, Applicants provisionally elect, with traverse, the species of SEQ ID NO: 1, which sets forth the amino acid sequence of the *N. scutatus* Phospholipase A₂ inhibitor (or "NSI") α chain.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on January 3, 2003.

Dated: January 3, 2003


Michelle Mustafa